Cooperative Throttle and Brake Fuzzy Control for ACC+Stop&Go Maneuvers

The authors are with the Industrial Computer Science Department, Instituto de Automática Industrial (CSIC), 28500 Madrid, SpainThe goal that a car be driven autonomously is far in the future and probably unreachable, but as a first step in that direction, adaptive cruise control (ACC) and Stop&Go maneuver systems are being developed. These kind of controllers adapt the speed of a car to that of the preceding one (ACC) and get the car to stop if the lead car stops. This paper presents one such system and related experiments performed on a real road with real cars. The driving system gets its input via an RTK DGPS device and communicates its positions to one another via a wireless local area network link. It outputs signals controlling the pressure on the throttle and brake pedals. The control system is based on fuzzy logic, which is considered best to deal with processes as complex as driving. Two mass produced Citroën Berlingo electric vans have been instrumented, providing them with computer controlled actuators over the brake and the throttle to achieve human-like driving. The results of the experiments show that the behavior of the vehicles is very close to human and that they adapt to driving incidences, increasing the safety of the driving and permitting cooperation with manually driven cars.This work was supported in part by the Spanish Ministry of Education under Grant ISAAC CICYT DPI2002-04064-C05-02, by the Spanish Ministry of Public Works under Grant COPOS BOE 280 22/11/2002, and by the Res. 22778, Citroën España S.A. under Contract “Adquirir nuevos conocimientos sobre la introducción de las tecnologías de la información en el mundo del automóvil y para difundirlos en los ámbitos científicos, empresariales y comerciales (AUTOPIA),” and by Cybecars-2 Project UE-STREP 28062, 6th Framework Programme, 2006.Peer reviewe

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)